SLDB

ANALYST NOTE: SOLID BIOSCIENCES INC. (SLDB) DATE: 2026-06-13

1. Structural Readiness

Conservative Entry: $8.02 Current Price: $8.33 Extension: +3.9% vs. conservative entry Breakout Level: $8.02 (Conservative) / $8.33 (Current)

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Gene & Cell Therapy (Tier Direct, High Confidence). Thesis Context: Solid Biosciences is a direct beneficiary of the secular shift toward gene and cell therapies for rare neuromuscular diseases. The company is not merely a speculative play but a primary developer of AAV-based gene therapies targeting Duchenne Muscular Dystrophy (DMD). The thesis is reinforced by the company's strategic alliance with Ultragenyx Pharmaceutical Inc., which provides a pathway for joint development and market introduction, validating the commercial potential of their pipeline. The "Gene & Cell Therapy" theme is the dominant driver, with no other conflicting secular themes present in the current setup.

3. The Business

Company Overview: Solid Biosciences is a clinical-stage biopharmaceutical company focused on developing gene therapies for neuromuscular and cardiac diseases. Business Model: The company operates on a high-risk, high-reward R&D model, funding operations through cash reserves and equity raises to progress candidates through clinical trials. Upon regulatory approval, the model shifts to commercial sales with milestone and royalty structures. Key Operations & Evidence (as of 2026-06-13):

• Pipeline Progress: The company has successfully advanced its lead candidate, SGT-003, into Phase 3. According to the March 19, 2026, filing, the Phase 3 "IMPACT DUCHENNE" trial began screening in October 2025, and the first participant was dosed in January 2026. Management expects initial data in the second half of 2026.
• Financial Liquidity: As of the March 31, 2026, filing (issued May 12, 2026), the company reported $380.7 million in cash, cash equivalents, and available-for-sale securities. Management explicitly stated that these funds are sufficient to fund operating expenses and capital requirements for at least twelve months from the date of issuance.
• Capital Raise: To support this runway, the company executed a private placement on March 9, 2026, raising approximately $226.3 million in net proceeds by issuing 14,973,257 shares and pre-funded warrants.
• Asset Expansion: In September 2024, the company acquired intellectual property for SGT-212 (a preclinical candidate) from FA212 LLC for an upfront payment of $1.0 million, with potential milestone payments up to $34.0 million and sales milestones up to $21.0 million.
• Platform Technology: The company is actively developing "dual gene expression" technology to bundle multiple therapeutic genes into single viral vectors, aiming to address broader muscle disorders beyond DMD.

4. Archetype and Conviction

Archetype: Growth Leader / Deep Value Recovery (Biotech Specific). Valuation Context: The financial spine indicates a forward consensus EPS of -1.93 for FY1 and -1.92 for FY2, reflecting the pre-revenue, high-burn nature of the company. The valuation is driven entirely by the probability-weighted value of the upcoming Phase 3 data readout for SGT-003. Conviction Stack:

• Thesis Strength: High. The DMD market is large (10,000–15,000 US cases) and underserved, with a clear unmet need for durable therapies.
• Evidence Quality: Strong. The evidence base is robust, moving from early clinical success (IGNITE DMD) to late-stage execution (IMPACT DUCHENNE). The 2026 filings confirm active dosing and a clear timeline for data.
• Rerating Potential: Significant. The market is currently pricing in the risk of failure; a positive Phase 3 readout in H2 2026 would likely trigger a major re-rating.
• ATR Analysis: The ATR is in the "very high" bucket (6–8%). While this increases the risk of sharp drawdowns, it also signals the structural quality required for a major move. The current price extension of +3.9% is healthy, suggesting the breakout is not yet overextended.

5. Invalidation, Strengthening, and Gaps

Invalidation Triggers:

• Fundamental: Any regulatory delay or safety signal emerging from the IMPACT DUCHENNE trial that forces a pause or redesign of the Phase 3 study.
• Financial: A significant reduction in cash runway below the 12-month management expectation without a new capital raise.

Strengthening Factors:

• Data Readout: Positive interim or final data from the IMPACT DUCHENNE trial in H2 2026.
• Capital Efficiency: Successful enrollment acceleration or cost reductions extending the cash runway beyond the 12-month horizon.
• Partnership: Announcement of a new strategic alliance or licensing deal for SGT-212 or cardiac candidates.

Evidence Gaps:

• Commercial Pricing: No evidence regarding potential pricing or reimbursement strategies for SGT-003, which is critical for long-term valuation.
• Competitive Landscape: Limited specific evidence on how SGT-003 compares to emerging competitors in the DMD space as of this date.
• Long-term Safety: While IGNITE DMD showed no long-term safety events, the Phase 3 data is not yet available to confirm long-term durability.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key risks: Phase 3 trial failure or safety signals; dilution from future equity raises if cash burn accelerates; regulatory delays in FDA interactions. Sizing hint: Position size should reflect the very high ATR (6.3%) and binary nature of the upcoming data readout; standard biotech sizing with tight stop management. Expected path: Price likely to trend higher on positive trial enrollment updates and anticipation of H2 2026 data, with volatility increasing as the data readout approaches. Expected horizon: 6 to 12 months, aligning with the anticipated data release in the second half of 2026.